Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs. Regulatory flexibilities afforded to neurodegenerative diseases as provided for in the Act of ALS.
2025 · 1st Quarter (Jan 1 - Mar 31)
BIOHAVEN PHARMACEUTICALS, INC.
Filed by DLA PIPER LLP (US).
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 21, 2025
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- DLA PIPER LLP (US)
- Filing UUID
- 28f77d11-2434-48dd-9e46-7b29257d3d0e
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.